로딩 중…
지수 로딩 중…
지니너스
389030· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩2,495-7.08%
2026-06-19
Price Chart
지니너스-11.21%
Financials
Investment Metrics(as of 2026-06-19)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | 97.41B KRW |
| Revenue | 10.24B KRW |
| Net Income | -17.03B KRW |
| Total Assets | 57.45B KRW |
| Net Assets | 27.39B KRW |
| Employees | 73 |
| Value | |
| P/B | 3.56x |
| P/S | 9.51x |
| FCF Yield | -8.64% |
| Profitability | |
| ROE | -62.18% |
| ROA | -29.65% |
| Op. Margin | -110.71% |
| Revenue Growth | -9.23% |
| Financial Health | |
| Debt Ratio | 109.73% |
| Total Debt | 8.29B KRW |
| FCF | -8.42B KRW |
| Cash | 26.95B KRW |
| Current Ratio | 1.42x |
| Performance | |
| 1Y Return | -11.21% |
| 1M Return | -30.60% |
| From 52W High | -61.50% |
| 1Y MDD | -60.21% |
| Trading | |
| Volume | 409,610 shares |
| Foreign Own. | 2.95% |
| Per Share | |
| EPS | -509 KRW |
| BPS | 698 KRW |
Company Info
Spun off from Samsung Genome Research Institute in 2018, this bio venture specializes in genome analysis and solution development. It offers NGS-based cancer genome diagnostic solution CancerSCAN, single-cell analysis platform Celinus, and cloud-based spatial omics analysis solution SPACEINSIGHT. The company is advancing new businesses like AI-based new drug development and digital pathology-based companion diagnostic solutions, while collaborating with domestic and international pharmaceutical companies using its single-cell and spatial omics analysis technologies.